Boryung Corporation (003850.KS)
KRW 10260.0
(-3.39%)
KRW 10260.0
(-3.39%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 114.28 Billion KRW | 4.38% |
| 2022 | 105.71 Billion KRW | 5.76% |
| 2021 | 81.81 Billion KRW | 51.17% |
| 2020 | 67.52 Billion KRW | 9.48% |
| 2019 | 62.69 Billion KRW | 55.06% |
| 2018 | 45.36 Billion KRW | -57.84% |
| 2017 | 93.62 Billion KRW | 145.1% |
| 2016 | 43.98 Billion KRW | -9.03% |
| 2015 | 41.77 Billion KRW | 2.93% |
| 2014 | 40.88 Billion KRW | 25.81% |
| 2013 | 32.53 Billion KRW | 77.8% |
| 2012 | 18.27 Billion KRW | -4.67% |
| 2011 | 19.18 Billion KRW | -28.96% |
| 2010 | 27.17 Billion KRW | 54.33% |
| 2009 | 17.44 Billion KRW | 17.53% |
| 2008 | 15.7 Billion KRW | -35.33% |
| 2007 | 22.96 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 30.82 Billion KRW | 249.55% |
| 2024 Q3 | 19.45 Billion KRW | -79.46% |
| 2024 Q1 | 27.09 Billion KRW | 19.27% |
| 2023 Q4 | 25.16 Billion KRW | -69.37% |
| 2023 Q1 | 79.32 Billion KRW | 2970.99% |
| 2023 Q3 | 82.15 Billion KRW | -7.83% |
| 2023 FY | - KRW | 4.38% |
| 2023 Q2 | 89.14 Billion KRW | 12.37% |
| 2022 Q2 | 32.18 Billion KRW | -57.86% |
| 2022 FY | - KRW | 5.76% |
| 2022 Q4 | 2.58 Billion KRW | -94.19% |
| 2022 Q3 | 44.47 Billion KRW | 38.19% |
| 2022 Q1 | 76.37 Billion KRW | 534.03% |
| 2021 Q2 | 14.14 Billion KRW | -45.47% |
| 2021 Q1 | 25.94 Billion KRW | 115.49% |
| 2021 FY | - KRW | 51.17% |
| 2021 Q3 | 49.54 Billion KRW | 250.21% |
| 2021 Q4 | 12.04 Billion KRW | -75.68% |
| 2020 Q1 | 19.66 Billion KRW | 21.63% |
| 2020 FY | - KRW | 9.48% |
| 2020 Q3 | 19.86 Billion KRW | 27.32% |
| 2020 Q4 | 12.03 Billion KRW | -39.38% |
| 2020 Q2 | 15.59 Billion KRW | -20.68% |
| 2019 Q2 | 19.07 Billion KRW | 13.09% |
| 2019 FY | - KRW | 55.06% |
| 2019 Q1 | 16.86 Billion KRW | 124.81% |
| 2019 Q3 | 15.66 Billion KRW | -17.88% |
| 2019 Q4 | 16.16 Billion KRW | 3.21% |
| 2018 Q4 | 7.5 Billion KRW | -32.05% |
| 2018 Q3 | 11.04 Billion KRW | 30.36% |
| 2018 FY | - KRW | -57.84% |
| 2018 Q2 | 8.46 Billion KRW | -34.96% |
| 2018 Q1 | 13.02 Billion KRW | -82.21% |
| 2017 Q3 | 7.93 Billion KRW | 61.41% |
| 2017 Q4 | 73.19 Billion KRW | 822.09% |
| 2017 FY | - KRW | 145.1% |
| 2017 Q1 | 7.79 Billion KRW | 38.07% |
| 2017 Q2 | 4.91 Billion KRW | -36.9% |
| 2016 FY | - KRW | -9.03% |
| 2016 Q2 | 14.64 Billion KRW | 76.9% |
| 2016 Q3 | 9.71 Billion KRW | -33.69% |
| 2016 Q4 | 5.64 Billion KRW | -41.89% |
| 2016 Q1 | 8.28 Billion KRW | -15.36% |
| 2015 Q4 | 9.78 Billion KRW | -10.96% |
| 2015 Q2 | 10.99 Billion KRW | 6.59% |
| 2015 Q1 | 10.31 Billion KRW | -12.41% |
| 2015 FY | - KRW | 2.93% |
| 2015 Q3 | 10.98 Billion KRW | -0.09% |
| 2014 Q1 | 10.87 Billion KRW | 2.59% |
| 2014 Q3 | 10.67 Billion KRW | 41.25% |
| 2014 Q4 | 11.77 Billion KRW | 10.34% |
| 2014 Q2 | 7.55 Billion KRW | -30.52% |
| 2014 FY | - KRW | 25.81% |
| 2013 Q2 | 11.63 Billion KRW | 153.27% |
| 2013 Q4 | 10.6 Billion KRW | 78.82% |
| 2013 FY | - KRW | 77.8% |
| 2013 Q1 | 4.59 Billion KRW | 17.39% |
| 2013 Q3 | 5.92 Billion KRW | -49.03% |
| 2012 FY | - KRW | -4.67% |
| 2012 Q1 | 4.53 Billion KRW | 158.22% |
| 2012 Q4 | 3.91 Billion KRW | -30.14% |
| 2012 Q3 | 5.59 Billion KRW | 32.25% |
| 2012 Q2 | 4.23 Billion KRW | -6.61% |
| 2011 Q4 | 1.75 Billion KRW | -58.22% |
| 2011 FY | - KRW | -28.96% |
| 2011 Q3 | 4.2 Billion KRW | -18.43% |
| 2011 Q2 | 5.15 Billion KRW | -38.05% |
| 2011 Q1 | 8.31 Billion KRW | 461.86% |
| 2010 Q2 | 10.51 Billion KRW | 90.89% |
| 2010 Q1 | 5.5 Billion KRW | 256.68% |
| 2010 FY | - KRW | 54.33% |
| 2010 Q4 | 1.47 Billion KRW | -84.4% |
| 2010 Q3 | 9.48 Billion KRW | -9.81% |
| 2009 Q3 | 3.62 Billion KRW | -55.23% |
| 2009 Q1 | 4.21 Billion KRW | 360.28% |
| 2009 Q2 | 8.1 Billion KRW | 92.25% |
| 2009 Q4 | 1.54 Billion KRW | -57.42% |
| 2009 FY | - KRW | 17.53% |
| 2008 Q4 | 915.62 Million KRW | -72.06% |
| 2008 Q1 | 4.73 Billion KRW | 4.21% |
| 2008 Q2 | 5.94 Billion KRW | 25.5% |
| 2008 FY | - KRW | -35.33% |
| 2008 Q3 | 3.27 Billion KRW | -44.91% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q2 | 6.06 Billion KRW | 27.81% |
| 2007 Q4 | 4.54 Billion KRW | -40.6% |
| 2007 Q1 | 4.74 Billion KRW | 0.0% |
| 2007 Q3 | 7.65 Billion KRW | 26.3% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -2252.412% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 19.153% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 278.475% |
| HANDOK Inc. | 35.06 Billion KRW | -225.916% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 11125.55% |
| Yuhan Corporation | 127.43 Billion KRW | 10.315% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -204.597% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 626.976% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 64.653% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -2190.195% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -655.962% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -3240.805% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -2424.922% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -222.062% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -2252.412% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 718.716% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -1643.536% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 331.86% |
| JW Holdings Corporation | 187.88 Billion KRW | 39.171% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 323.095% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 59.705% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -28.096% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 408.33% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -765.19% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -866.262% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -512.646% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -2252.412% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | -107.898% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 30.698% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -28.096% |
| Yuhan Corporation | 127.43 Billion KRW | 10.315% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -241.404% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -1393.995% |
| Suheung Co., Ltd. | 77.02 Billion KRW | -48.371% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -28.096% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -211.969% |
| Korea United Pharm Inc. | 70.78 Billion KRW | -61.469% |
| CKD Bio Corp. | -1.63 Billion KRW | 7109.633% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -129.527% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -250.992% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -210.478% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 408.33% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | -83.494% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 473.878% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -655.962% |
| JW Lifescience Corporation | 50.82 Billion KRW | -124.847% |